Shr-8068
Advanced Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 81/ 100
Competitive context
520 Active assets in the Advanced Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Huaier Granule Tongji Hospital | Phase 4 | BBB |
Adefovir Bukwang Pharmaceutical | Phase 4 | BBB |
Sorafenib Bayer | Phase 4 | BBB |
Theprubicin RWTH Aachen University | Phase 4 | BB |
Carboplatin AstraZeneca | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Shr-8068 is also rated in:
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →